Although several markers of tumor proliferation and metabolism have been identified in GBM and are used clinically (EGFRvIII amplification, MGMT promoter methylation, IDH1 mutation status), prognostic markers of invasive capacity are largely lacking. Here, MGMT is linked to glioblastoma.